Transcat, Inc. (NasdaqGM:TRNS) will look for acquisitions. During the company?s first quarter fiscal year 2024 financial results, Lee Rudow, President and Chief Executive Officer said that ?Over the course of fiscal 2024, we expect to continue to deploy capital to margin and revenue-enhancing initiatives along with the execution of our ongoing acquisition and integration strategy?. ?As we look forward, we expect to deliver strong performance throughout the balance of fiscal 2024.
We will continue to execute our acquisition strategy to add capabilities and expertise, expand our geographic footprint into important regional markets and to bolt-on opportunities that leverage our current lab infrastructure. From both an organic and acquisitive perspective, our focus will remain on our diverse strategic channels, including calibration, pipettes, instrument rentals and [NEXA's] suite of cost control and compliance services?.
Transcat, Inc. is a provider of accredited calibration services, cost control and optimization services, and distribution and rental of value-added professional grade handheld test, measurement, and control instrumentation. The Company is focused on providing services and products to highly regulated industries, particularly the life science industry, which includes pharmaceutical, biotechnology, medical device and other FDA-regulated businesses. Through its Service segment, it offers calibration, repair, inspection, analytical qualifications, preventative maintenance, consulting and other related services, a majority of which are processed through its asset management system, CalTrak, and its online customer portal, C3. It also provides permanent and periodic onsite services, mobile calibration services, pickup and delivery and in-house services. Through its Distribution segment, it sells and rents national and proprietary brand instruments to customers globally.